Tasigna and Gastrointestinal inflammation - a phase IV clinical study of FDA data

Summary:

Gastrointestinal inflammation is reported as a side effect among people who take Tasigna (nilotinib hydrochloride monohydrate), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Sertraline, and have Diabetes.

The phase IV clinical study analyzes which people have Gastrointestinal inflammation when taking Tasigna. It is created by eHealthMe based on reports of 31,413 people who have side effects when taking Tasigna from the FDA, and is updated regularly.

What is Tasigna?

Tasigna has active ingredients of nilotinib hydrochloride monohydrate. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 31,535 Tasigna users. Check the latest studies of Tasigna.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 541 drugs and 548 conditions by eHealthMe. Check the latest studies of Gastrointestinal inflammation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

31,413 people reported to have side effects when taking Tasigna.
Among them, 37 people (0.12%) have Gastrointestinal inflammation.

Could Tasigna cause Gastrointestinal inflammation?

Among these 37 people:

How long have people been on Tasigna when they have Gastrointestinal inflammation? *

What is the gender of people who have Gastrointestinal inflammation when taking Tasigna? *

female: 64.86 %
male: 35.14 %

What is the age of people who have Gastrointestinal inflammation when taking Tasigna? *

What are other drugs people take besides Tasigna? *

What are other side effects people have besides Gastrointestinal inflammation? *

Pain: 33 people, 89.19%
Weakness: 24 people, 64.86%
Malaise (a feeling of general discomfort or uneasiness): 23 people, 62.16%
Fatigue (feeling of tiredness): 21 people, 56.76%
Nausea (feeling of having an urge to vomit): 20 people, 54.05%
Pain In Extremity: 18 people, 48.65%
Diarrhea: 18 people, 48.65%
Weight Decreased: 18 people, 48.65%
Itching: 18 people, 48.65%
Discomfort: 18 people, 48.65%

What are the existing conditions these people have? *

Diabetes: 4 people, 10.81%
High Blood Cholesterol: 3 people, 8.11%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 5.41%
Gastric Disorder (disease of stomach): 2 people, 5.41%

* Approximation only. Some reports may have incomplete information.

Do you take Tasigna and have Gastrointestinal inflammation?

- Check whether Gastrointestinal inflammation is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tasigna:

Tasigna (31,535 reports)

Gastrointestinal inflammation treatments and more:

Gastrointestinal inflammation (9,479 reports)

How severe was Gastrointestinal inflammation and when was it recovered:

Gastrointestinal inflammation in Tasigna

Expand to all the drugs that have ingredients of nilotinib hydrochloride monohydrate:

Gastrointestinal inflammation and drugs with ingredients of nilotinib hydrochloride monohydrate (38 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tasigna:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastrointestinal inflammation:

Gastrointestinal inflammation (541 drugs)

Browse all the conditions that are associated with Gastrointestinal inflammation:

Gastrointestinal inflammation (548 conditions)

Related publications that referenced our studies

Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .
Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, Lachmann RH, Shah N, Patel SY, Booth C, Runz H, "Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann–Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn9s disease", Gut, 2016 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on nilotinib hydrochloride monohydrate (the active ingredients of Tasigna) and Tasigna (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.